Search

先进的介入性肺脏病学技术正在彻底改变肺癌的诊断和治疗，通常尽量将多种侵入性手术的需求降至最低。

… Tuesday, January 16, 2018 先进的 介入性肺病学 (IP) 技术正在彻底改变肺癌的诊断和治疗。经专门培训的医生可以通过微创支气管镜检查准确诊断和分期肺癌，并为恶性气道、胸膜腔和肺实质疾病患者提供微创治疗和姑息治疗。 在 Memorial Sloan Kettering Cancer Center (MSK)， 自 2008 年与两位主治医师一起成立 IP 部门以来， 我们一直在介入性肺科学领域处于领先地位。( www.mskcc.org/IP )。我们的团队在肺癌患者症状管理循证临床实践指南的开发  (1) 、该领域医生培训考试的有效性  (2) ，以及最近用于癌症分期的超声引导下经支气管针吸活检术

Anthony Antonelli is an unlikely scientist. A “rambunctious” child, born in Queens and raised on Long Island, he was smart and creative — but not very keen on academics. “If it wasn’t a guitar or skateboard, I wasn’t interested,” he remembers.

… Friday, September 30, 2022 Anthony Antonelli Anthony Antonelli  is an unlikely scientist. A “rambunctious” child, born in Queens and raised on Long Island, he was smart and creative — but not very keen on academics. “If it wasn’t a guitar or skateboard, I wasn’t interested,” he remembers. Finding the

Memorial Sloan Kettering Cancer Center (MSK) today announced details of strategic real estate investments that will support the world class cancer center into the future. In March 2022, MSK announced plans to build a new, state-of-the-art cancer care Pavilion on the Upper East Side campus to address the evolving cancer care needs of patients over the next century.

… Monday, September 12, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced details of strategic real estate investments that will support the world class cancer center into the future. In March 2022, MSK announced plans to build a new, state-of-the-art cancer care Pavilion on the Upper East

September is Pediatric Cancer Awareness Month and at Memorial Sloan Kettering Cancer Center, we continue to work to bring awareness and advance research and treatments for our youngest and most vulnerable patients — not only in September, but every day.

… Wednesday, September 29, 2021 September is Pediatric Cancer Awareness Month and at Memorial Sloan Kettering Cancer Center, we work to bring awareness and advance research and treatments for our youngest and most vulnerable patients every day. To advance this cause, the 2021 Kids Walk for MSK Kids was

In this interview, hematologic oncologist Eytan Stein, Director of the Program for Drug Development in Leukemia, talks about the latest advances in treatment for AML and how people can benefit from receiving their treatment at MSK.

… Monday, November 18, 2024 Acute myeloid leukemia (AML) is one of the most common types of blood cancer. The word “acute” means that the cancer can advance quickly and needs to be treated right away. The word “myeloid” refers to the type of blood cells that are cancerous. Myeloid cells are blood cells

Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.

… Monday, May 16, 2022 Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan

A recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.

… Friday, February 8, 2019 Summary People newly diagnosed with peripheral T cell lymphoma have traditionally been treated with chemotherapy. A recent study showed that adding a drug called brentuximab vedotin to chemotherapy could stop the disease from progressing and improve survival. Peripheral T cell

Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows.

… Thursday, January 27, 2022 Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows. The new class of AAAS Fellows includes 564 scientists, engineers

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

… Thursday, April 9, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.

… Thursday, June 11, 2020 The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.  (1) The best objective response rate (ORR) was 30 percent (95%